Sensitive Osteosarcoma Diagnosis Through Five-Base Telomerase Product-Triggered CRISPR-Cas12a Enhanced Rolling Circle Amplification

2021 ◽  
Author(s):  
Xing Zhou ◽  
Jun-Liang Zhang ◽  
Meng-Han Chang ◽  
Gentao Fan ◽  
Xiao-Zhou Liu ◽  
...  
Keyword(s):  
Early Diagnosis ◽  
Bone Tumor ◽  
Rolling Circle Amplification ◽  
Mesenchymal Cells ◽  
Pivotal Role ◽  
Sensitive Detection ◽  
Malignant Bone Tumor ◽  
Rolling Circle ◽  
Primary Malignant Bone Tumor

Osteosarcoma is the most frequent primary malignant bone tumor composed of mesenchymal cells producing osteoid and immature bone. Sensitive detection of telomerase plays a pivotal role for the early diagnosis...

Low-heat Treated Intercalary Autograft Reconstruction in Limb Salvage of Primary Malignant Bone Tumor

2007 ◽  
Vol 42 (3) ◽  
pp. 291
Author(s):  
Han-Soo Kim ◽  
Hyun Guy Kang ◽  
Jai Ho Cho ◽  
Kap Jung Kim ◽  
Joo Han Oh ◽  
...  
Keyword(s):  
Limb Salvage ◽  
Bone Tumor ◽  
Malignant Bone Tumor ◽  
Primary Malignant Bone Tumor ◽  
Heat Treated

A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 11525-11525
Author(s):  
Lina Tang ◽  
Xiaohui Niu ◽  
Zhen Wang ◽  
Qiqing Cai ◽  
Chongqi Tu ◽  
...  
Keyword(s):  
Phase Ii ◽  
Malignant Fibrous Histiocytoma ◽  
Bone Tumor ◽  
Ewing Sarcoma ◽  
Phase Ii Study ◽  
Fibrous Histiocytoma ◽  
Malignant Bone Tumor ◽  
Eligibility Criteria ◽  
Primary Malignant Bone Tumor ◽  
Study Results

11525 Background: Primary malignant bone tumors are rare forms of cancer and include mainly bone sarcomas, which are categorized into 3 common types based on tissue origin: osteosarcoma, chondrosarcoma and Ewing sarcoma. A phase II trial was designed to explore the anlotinib activity in patients with relapsed or metastatic primary malignant bone tumor. Methods: Eligible pts were received 12mg of anlotinib once daily, 2 weeks on and 1 week off until progression or unacceptable toxicity. Key-eligibility criteria were aged 14-70 years, histologically confirmed diagnosis of osteosarcoma, chondrosarcoma, bone derived malignant fibrous histiocytoma, giant cell tumor, Ewing sarcoma and PNET, confirmed previous chemotherapy failure, ECOG 0-1(0-2 for amputation pts), required at least one measurable lesion. We observed PFS, OS, ORR, DCR and AE in this study. Results: From August 2018 to April 2019, 42 pts were included. Of 42 efficacy-evaluable pts, 25 were man, median age was 28 (14-68) years. There were 29 pts of osteosarcoma, 9 pts of chondrosarcoma, 3pts of Ewing sarcoma and 1 pt of bone derived malignant fibrous histiocytoma. The progression-free rate at 12 weeks (PFR12weeks), ORR and DCR were 71.3%, 9.52% and 78.57%. Median PFS was 5.26 months (95%CI = 3.48-8.44). Median OS was 11.40 months (95%CI = 10.09, [ ). Median PFS of osteosarcoma and chondrosarcoma was 4.83 months (95%CI = 3.48, 7.13 ) and 2.76 months (95%CI = 1.31, [ ) respectively. The most common Gr 3-5 anlotinib-related AEs were hypertension (19.05%), hypertriglyceridemia (9.52%), hand-foot syndrome (7.14%), and proteinuria (4.76%). Conclusions: The phase II study shows a promising activity of anlotinib in patients with relapsed or metastatic primary malignant bone tumor and an acceptable toxicity. Clinical trial information: NCT03527888 .

Treatment of Primary Malignant Bone Tumor

1983 ◽  
Vol 18 (6) ◽  
pp. 1221
Author(s):  
Han Koo Lee ◽  
Min Young Chung ◽  
Yong Hoon Kim ◽  
Youn Soo Park
Keyword(s):  
Bone Tumor ◽  
Malignant Bone Tumor ◽  
Primary Malignant Bone Tumor
Sign in / Sign up

Export Citation Format

Share Document